시신경척수염범위질환 치료의 최신 지견

키워드

참고문헌 (61)

1. Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
2. Mori M, "Worldwide prevalence of neuromyelitis optica spectrum disorders", J Neurol Neurosurg Psychiatry, 89, pp.555~556 (2018)
3. Flanagan EP, "Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum", Ann Neurol, 79, pp.775~783 (2016)
4. Jarius S, "Neuromyelitis optica", Nat Rev Dis Primers, 6, pp.85~ (2020)
5. Jarius S, "MOG-IgG in NMO and related disorders: a multicenter study of 50patients. Part 3: brainstem involvement - frequency, presentation and outcome", J Neuroinflammation, 13, pp.281~ (2016)
6. Bennett JL, "B lymphocytes in neuromyelitis optica", Neurol Neuroimmunol Neuroinflamm, 2, pp.e104~ (2015)
7. Stiebel-Kalish H, "Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?", Neurol Neuroimmunol Neuroinflamm, 6, pp.e572~ (2019)
8. Kleiter I, "Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions", Neurol Neuroimmunol Neuroinflamm, 5, pp.e504~ (2018)
9. 김수현, "Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels", Journal of Clinical Neurology, 9(1), pp.36~42 (2013), 대한신경과학회[DOI]
10. Bonnan M, "Plasma exchange in severe attacks of neuromyelitis optica", Mult Scler Int, 2012, pp.787630~ (2012)
11. Kleiter I, "Neuromyelitis optica : evaluation of 871 attacks and 1, 153 treatment courses", Ann Neurol, 79, pp.206~216 (2016)
12. Schwab I, "Intravenous immunoglobulin therapy : how does IgG modulate the immune system?", Nat Rev Immunol, 13, pp.176~189 (2013)
13. Elsone L, "Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica : experience in 10 patients", Mult Scler, 20, pp.501~504 (2014)
14. Lin J, "Intravenous immunoglobulin as the rescue treatment in NMOSD patients", Neurol Sci, 42, pp.3857~3863 (2021)
15. Costanzi C, "Azathioprine : tolerability, efficacy, and predictors of benefit in neuromyelitis optica", Neurology, 77, pp.659~666 (2011)
16. Elsone L, "Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients : a multicentre retrospective observational study from the UK", Mult Scler, 20, pp.1533~1540 (2014)
17. Jiao Y, "Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders : a case series study", BMC Neurol, 18, pp.47~ (2018)
18. Chen H, "The Efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China", Clin Neuropharmacol, 39, pp.81~87 (2016)
19. Huh SY, "Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder", JAMA Neurol, 71, pp.1372~1378 (2014)
20. Jacob A, "Treatment of neuromyelitis optica with mycophenolate mofetil : retrospective analysis of 24 patients", Arch Neurol, 66, pp.1128~1133 (2009)
21. Chen H, "Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder", Eur J Neurol, 24, pp.219~226 (2017)
22. Yang Y, "Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder", J Neurol Sci, 385, pp.192~197 (2018)
23. Cree BA, "An open label study of the effects of rituximab in neuromyelitis optica", Neurology, 64, pp.1270~1272 (2005)
24. Kim SH, "Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years", Arch Neurol, 68, pp.1412~1420 (2011)
25. Pellkofer HL, "Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab", Neurology, 76, pp.1310~1315 (2011)
26. Kim SH, "A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder", JAMA Neurol, 70, pp.1110~1117 (2013)
27. Kim SH, "Treatment Outcomes With rituximab in 100 patients with neuromyelitis optica : influence of FCGR3A polymorphisms on the therapeutic response to rituximab", JAMA Neurol, 72, pp.989~995 (2015)
28. Olivieri G, "Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder", Neurol Sci, 36, pp.2301~2302 (2015)
29. Zephir H, "Rituximab as first-line therapy in neuromyelitis optica : efficiency and tolerability", J Neurol, 262, pp.2329~2335 (2015)
30. Kim SH, "Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment", J Neurol Neurosurg Psychiatry, 90, pp.486~487 (2019)
31. Tahara M, "Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders(RIN-1 study) : a multicentre, randomised, double-blind, placebo-controlled trial", Lancet Neurol, 19, pp.298~306 (2020)
32. Cohen M, "Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab : Results from a bicentric study", J Neurol Sci, 373, pp.335~338 (2017)
33. Lebrun C, "only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders", Neurol Ther, 7, pp.373~383 (2018)
34. Ellwardt E, "Monitoring B-cell repopulation after depletion therapy in neurologic patients", Neurol Neuroimmunol Neuroinflamm, 5, pp.e463~ (2018)
35. Li T, "Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab", J Neuroimmunol, 316, pp.107~111 (2018)
36. Kim SH, "Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder", Neurochem Int, 130, pp.104347~ (2019)
37. Avouac A, "rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases", Neurol Neuroimmunol Neuroinflamm, 8 (2021)
38. Marcinno A, "Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders", Neurol Neuroimmunol Neuroinflamm, 5, pp.e498~ (2018)
39. Jeong IH, "Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints", Mult Scler, 22, pp.329~339 (2016)
40. Torres J, "Analysis of the treatment of neuromyelitis optica", J Neurol Sci, 351, pp.31~35 (2015)
41. Nikoo Z, "Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder : a randomized clinical trial", J Neurol, 264, pp.2003~2009 (2017)
42. Uzawa A, "Cytokine and chemokine profiles in neuromyelitis optica : significance of interleukin-6", Mult Scler, 16, pp.1443~1452 (2010)
43. Matsushita T, "Characteristic cerebrospinal fluid cytokine", chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis, 2013, pp.8, e61835~
44. Araki M, "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study", Neurology, 82, pp.1302~1306 (2014)
45. Ringelstein M, "Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder", JAMA Neurol, 72, pp.756~763 (2015)
46. Zhang C, "Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder(TANGO) : an open-label, multicentre, randomised, phase 2 trial", Lancet Neurol, 19, pp.391~401 (2020)
47. Weinstock-Guttman B, "Study of mitoxantrone for the treatment of recurrent neuromyelitis optica(Devic disease)", Arch Neurol, 63, pp.957~963 (2006)
48. Kim SH, "Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica", Arch Neurol, 68, pp.473~479 (2011)
49. Ramanathan RS, "Treatment of neuromyelitis optica", neuromyelitis optica spectrum disorders with methotrexate, 2014, pp.14, 51~
50. Chen B, "Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder", Sci Rep, 7, pp.831~ (2017)
51. Kageyama T, "Combination of cyclosporine a with corticosteroids is effective for the treatment of neuromyelitis optica", J Neurol, 260, pp.627~634 (2013)
52. Min JH, "Development of extensive brain lesions following fingolimod(FTY720)treatment in a patient with neuromyelitis optica spectrum disorder", Mult Scler, 18, pp.113~115 (2012)
53. Kim SH, "Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?", Mult Scler, 18, pp.1480~1483 (2012)
54. Ayzenberg I, "Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder : a multicenter retrospective study", J Neurol, 263, pp.575~582 (2016)
55. Azzopardi L, "Alemtuzumab use in neuromyelitis optica spectrum disorders : a brief case series", J Neurol, 263, pp.25~29 (2016)
56. Pittock SJ, "Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study", Lancet Neurol, 12, pp.554~562 (2013)
57. Pittock SJ, "Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder", N Engl J Med, 381, pp.614~625 (2019)
58. Cree BAC, "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder(N-MOmentum) : a double-blind, randomised placebo-controlled phase 2", 3 trial, 2019, pp.394, 1352~1363
59. Traboulsee A, "Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial", Lancet Neurol, 19, pp.402~412 (2020)
60. Igawa T, "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nat Biotechnol, 28, pp.1203~1207 (2010)
61. Yamamura T, "Trial of satralizumab in neuromyelitis optica spectrum disorder", N Engl J Med, 381, pp.2114~2124 (2019)

관련 논문AI추천